A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
by on Friday, August 17th, 2012 | No Comments
Condition: Prostate Cancer
Intervention: Drug: Drug: 99mTc-MIP-1404
Sponsors: Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.
Recruiting – verified August 2012
Read more from the original source: A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology